3.8 Article

The management of lomustine overdose in malignant glioma patients

Journal

NEURO-ONCOLOGY PRACTICE
Volume 1, Issue 4, Pages 178-183

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nop/npu023

Keywords

CCNU; glioma; lomustine; myelosuppression; overdose; PCV

Ask authors/readers for more resources

Lomustine is an oral alkylating drug commonly used for brain tumor patients. Recently, the lomustine-containing PCV polychemotherapy regime (procarbazine, CCNU/lomustine, and vincristine) in combination with radiotherapy has become the standard of care for anaplastic oligodendroglioma with 1p/19q codeletion and high-risk low-grade glioma. Here, we review the literature of all reported cases of lomustine overdose, highlight complications by exemplifying a case of inadvertent lomustine overdose, and outline the management of this potential complication of outpatient PCV therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available